• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Vaccine-In-A-Pill For Norovirus, The Infamous Winter Bug, Performs Well In Early Trials

March 14, 2025 by Deborah Bloomfield

A vaccine against norovirus, the dreaded “winter vomiting bug”, could be closer than you think: early clinical trials have returned positive results for a vaccine candidate that is taken orally as a pill. The trial targeted older adults, who are particularly at risk from severe complications from the infection that causes annual misery for so many.

ADVERTISEMENT

When we say “vaccine” we immediately think “injection”, but there is a precedent for oral vaccines – most notably the oral polio vaccine that millennials of a certain age almost certainly received as a small children. 

In this case, the pill, called VXA-G1.1-NN, has been designed to deliver a harmless viral vector carrying a norovirus protein directly to the small intestine. This is not the only norovirus vaccine currently in trials – for example, a trial of an mRNA vaccine was launched in the UK last year – but developers Vaxart believe there are a lot of advantages to their pill format.

Writing on their website, they explain that the platform is adaptable to both existing and emerging diseases, avoids problems with storage, eliminates the risk of needlestick injuries, and promotes strong immune responses at mucosal barrier surfaces.

This last point is particularly important with norovirus. It means that, in response to the vaccine, the body builds its defenses right at the places where the virus is likely to try and gain entry – the lining of the nose and mouth, for instance. 

“Given that norovirus is transmitted through mucosal routes, a vaccine that elicits protective immunity at barrier surfaces would be desirable,” write the study authors in their paper. 

Norovirus outbreaks are so hard to control because as few as 10 viral particles are enough to spark an infection. The virus is not easily killed by hand sanitizers, so regular soap and water and surface cleaners with bleach are the best tools we have to stop it. However, given that someone who’s been struck down with the disease can remain infectious for weeks after their symptoms have gone, it’s easy to see how the virus can spread like wildfire in settings like schools, care homes, and cruise ships. 

ADVERTISEMENT

Most people will recover from a bout of norovirus within a few very unpleasant days, but the consequences can be much more serious in older people. Severe vomiting and diarrhea bring a risk of dehydration, which can be deadly if not treated. 

Unfortunately, it’s precisely this group of people who are more difficult to target with vaccines. The immune system starts to wind down a bit as we age, thanks to a process called immunosenescence. Basically, it becomes harder to elicit a strong response from it with a vaccine.

Add to that the fact that norovirus is not just one virus, but rather a group of them, and you have a complex problem on your hands.

However, Vaxart’s candidate vaccine pill appears to be hitting the right notes. In the trial, 65 adults aged 55-80 were stratified into three cohorts – low, medium, and high dose – and a placebo group. They were further divided into younger (55-65) and older (66-80) age groups. 

ADVERTISEMENT

Each treatment group was given two pills, with the second 28 days after the first as a booster. The vaccine was found to be safe, with no serious adverse events occurring.

Better still, it was effective. The team found that the pills elicited a strong antibody response in blood, saliva, and nasal secretions. The mucosal immunity lasted for 210 days, showing it was not a short-term response. 

“The mucosal response induced by VXA-G1.1-NN has the potential to inhibit infection, viral shedding, and transmission,” the authors conclude. While additional, larger trials will now be needed, they believe it is a positive first step. So much so, Vaxart just announced they are launching a Phase 1 trial for a second-generation norovirus vaccine pill, to run concurrently. 

For anyone who was struck down during the worse-than-usual norovirus season that hit UK and US headlines recently, this will be music to their ears.

ADVERTISEMENT

The study is published in the journal Science Translational Medicine. 

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Chinese court rules against #MeToo plaintiff
  2. Deere workers reject six-year labor contract
  3. What Was The Egyptian Book Of The Dead?
  4. Mysterious Low Rumbling Noise Heard In Florida For Years Gets NSFW Explanation

Source Link: Vaccine-In-A-Pill For Norovirus, The Infamous Winter Bug, Performs Well In Early Trials

Filed Under: News

Primary Sidebar

  • When Red Devil Spiders Arrived On A New Island, Their Genome Dramatically Shrank In Half
  • Is This The World’s Oldest Story? Ancient Human Tale About The Seven Sisters May Be From 100,000 BCE
  • This Pill Is Actually A Tiny Printer That Repairs Internal Injuries Using Biocompatible Ink
  • “This Is Amazing”: Scientists Have Found Evidence Of A Long-Lost World Deep Within The Earth
  • From The Shiniest World To Lava And Eternal Darkness, These Are The Weirdest Known Planets
  • Do Sharks Have Bones?
  • The Zombie Awakens: A Volcano Is Showing “First Signs” Of Unrest After 700,000 Years Of Quiet
  • Two Of The World’s Biggest Earthquakes Seem To Be Synched Together
  • California Has A New State Snake, And It’s A 1.6-Meter-Long Giant
  • Experimental Nanoparticle “Super-Vaccines” Stop Breast, Pancreatic, And Skin Cancers In Their Tracks
  • New Nightmare Fuel Unlocked: Watch The First Known Capture Of A Shrew By A False Widow Spider
  • Peculiar Glow In The Milky Way Might Be Dark Matter Signature
  • “I Was Scared To Death”: Missouri’s Great Cobra Scare Of 1953 Was Eventually Solved After 35 Years
  • Two Spacecraft To Fly Through Comet 3I/ATLAS’s Ion Tail – Will They Be Able To Catch Something?
  • Pioneering Heavy Water Detection Suggests Earth’s Water Might Be Older Than The Sun
  • PhD Students’ Groundbreaking New Technique Rescues JWST’s Highest Resolution Data
  • Popcorn-Like Parasites And Weird Worms Among 14 New Species Discovered In The World’s Oceans
  • Poem From 1181 CE Cairo Appears To Reference A Rare Galactic Supernova
  • With “Iridescent Live Colors”, Newly Discovered Beautiful Dwarfgoby Lives Up To Its Name (Mostly)
  • “Anti-Tail” And Odd 594-Kilometer Feature Found On Interstellar Object 3I/ATLAS By Keck Observatory
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version